49.52
1.47 (3.06%)
| Previous Close | 48.05 |
| Open | 48.05 |
| Volume | 2,548,926 |
| Avg. Volume (3M) | 2,175,696 |
| Market Cap | 7,580,699,136 |
| Price / Earnings (TTM) | 17.31 |
| Price / Earnings (Forward) | 38.02 |
| Price / Sales | 11.37 |
| Price / Book | 13.00 |
| 52 Weeks Range | |
| Earnings Date | 3 Aug 2026 |
| Profit Margin | 10.13% |
| Operating Margin (TTM) | 7.13% |
| Diluted EPS (TTM) | 0.250 |
| Quarterly Revenue Growth (YOY) | 90.40% |
| Quarterly Earnings Growth (YOY) | -96.60% |
| Total Debt/Equity (MRQ) | 107.29% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -61.02 M |
| Levered Free Cash Flow (TTM) | -87.64 M |
| Return on Assets (TTM) | 7.26% |
| Return on Equity (TTM) | 19.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | TG Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.74% |
| % Held by Institutions | 63.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Clearbridge Investments, Llc | 31 Mar 2026 | 3,210,930 |
| Congress Asset Management Co | 31 Mar 2026 | 2,168,081 |
| Hood River Capital Management Llc | 31 Mar 2026 | 1,569,171 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |